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SUMMARY
Aspergillus is a phagocyte opportunistic fungus that causes aspergillosis, an unusual disease in patients with AIDS. Six cases of 
fungal ball in patients with AIDS are reported here. In this group, all patients had hemoptysis and tuberculosis as the underlying lung 
disease. The diagnosis of pulmonary fungus ball was based on the clinical and radiographic feature, combined with serological and 
mycological evidence of Aspergillus fumigatus.
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INTRODUCTION
Pulmonary aspergillosis has various presentations depending 
largely on the immune competence of the patient, the type of exposure, 
and the presence of an underlying disease. Aspergillus fumigatus 
is the predominant species cultured from the respiratory tract that 
can cause acute angioinvasive pulmonary aspergillosis and other 
chronic forms of infection. These entities include chronic necrotizing 
aspergillosis (semi-invasive), allergic bronchopulmonary aspergillosis, 
intracavitary colonization (fungus ball), bronchocentric granulomatosis 
or hypersensitivity pneumonitis. The distinction among subacute, 
acute angioinvasive pulmonary aspergillosis, chronic necrotizing 
aspergillosis and fungus ball has not been rigorously defined and an 
overlap in clinical and radiological features among these different entities 
probably exist3,10,16,20. As Aspergillus is a phagocyte opportunistic fungus, 
aspergillosis is unusual in patients with AIDS, except in late stages of 
the viral disease14. Fungus ball caused by A. fumigatus is a noninvasive 
form of pulmonary disease that results from a lung fungal colonization. 
The empty, post-treatment tuberculosis cavity is the main predisposing 
factor for fungal colonization in most patients and hemoptysis is the only 
serious complication17,22.
Fungus ball may be divided into simple or complex. While the first 
one occurs in a cavity without surrounding parenchymal disease, the 
other occurs in a thick-walled cavity with surrounding parenchymal 
inflammation and is associated with higher morbidity and mortality2,7. 
The diagnosis of pulmonary aspergillosis is based on clinical, 
radiological, and mycological data.
On radiographs, pulmonary fungus ball appears as a solid rounded 
mass of unique density, sometimes mobile, within a spherical or ovoid 
cavity, and separated from the wall of the cavity by airspace of variable 
size and shape21,25. Chest tomography (CT) demonstrates excellent 
advantage from chest radiograph for the intracavitary colonization 
diagnostic, showing the presence of a mass in a pre-existing cavity while 
this fungus ball is not yet apparent on radiography3,11,16,26.
The most consistent diagnostic features of fungus ball are 
hemoptysis, chronic cough, usually productive, and an upper-lobe, 
mobile intracavitary mass with an air crescent in the periphery seen on 
the chest radiograph. Precipitating antibodies to species of Aspergillus 
(radial immunodiffusion) in the patients serum are found in virtually all 
patients, it has > 95% sensitivity for fungus ball, except in HIV-infected 
patients9,22,23. But a definitive diagnosis is established by microscopical 
demonstration of the septate hyphae and conidiophore of Aspergillus 
and/or culturing the Aspergillus from percutaneous aspirate/biopsy, 
fiberoptic bronchoscopy and resected specimens of the cavity19. 
Sometimes the cultures from material taken from surgical specimens 
are negative because of non-viable organisms within the fungal mass 
and/or secondary bacterial colonization9. Besides those, there are non-
culture-based microbiological methods to facilitate rapid diagnosis and 
to monitor infection progression and response to therapy. Promising 
methods include antigen-based assays (serology), metabolite detection, 
and molecular detection of fungal DNA from body fluid samples3,10. 
Pulmonary aspergillosis is rarely found in HIV positive patients, 
mainly in comparison with its prevalence in other risk group as patients 
with conditions that produce a similar degree of immunosuppression, 
such as organ transplantation, lymphoma and leukemia11,13. Pulmonary 
fungus ball in HIV-infected patient differs in several features from 
those in the immunocompetents. HIV positive patients are particularly 
susceptible to cavitary lung disease, including pneumatoceles secondary 
to Pneumocystis jirovecii pneumonia and tuberculosis, as well as 
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necrotizing bacterial pneumonias. These patients are less likely to 
significant hemoptysis. 
Treatment has to be individualized, depending on the severity of the 
symptoms, extent and location of the pulmonary involvement, relationship 
to other diseases, and the patient’s general condition. Thus, treatment of 
fungal ball must be adapted specifically to each patient, with the entire 
clinical presentation dictating the appropriate management. Treatment 
with a combination of antiretroviral and antifungal therapy appears to be 
effective in improving the clinical and radiographic outcomes of patients 
with HIV infection and pulmonary fungus ball6,8,21. 
In our study all patients presented a solid round mass, which was 
located in a single spherical, or ovoid cavity, therefore we termed it as 
fungus ball. Medical records were reviewed years after diagnosis of 
fungus ball, we considered that those patients didn’t outcome to chronic 
necrotizing aspergillosis or invasive disease. The rarity in those reports 
of pulmonary fungus ball in patients with AIDS indicates the importance 
of describing this series of six cases.
MATERIAL AND METHODS
In order to identify cases of possible fungus ball in HIV infected 
individuals, we retrospectively reviewed 485 cases of fungus ball diagnosed 
in the Mycology Laboratory (Santa Casa - Complexo Hospitalar, Porto 
Alegre, RS, Brazil), from 1980 to 2008. Charts, chest radiographs, 
CT scans, data from mycology cultures, serum immunodiffusion, 
bronchoscopic and surgical specimens, HIV testing, viral loads, and CD4 
levels were evaluated. Patients were included if they: (1) had a suggestive 
chest radiograph of fungus ball and evidence from culture, serum radial 
immunodiffusion (ID), pathologic specimen with Aspergillus spp., or if they 
had CT scan evidence of fungus ball and (2) were HIV-infected based on 
a positive enzyme-linked immunosorbent assay result that was confirmed 
by Western blot. Patients were excluded if charts and/or radiographs could 
not be obtained, if they were HIV-negative as determined by enzyme-linked 
immunosorbent assay, or if no HIV test had been performed.
Clinical presentation was evaluated in each case. When follow-up 
was available, the patients’ subsequent treatment, symptoms, radiographs, 
laboratory results, and clinical findings were recorded. Disease 
progression or improvement was defined radiographically (change in size 
of fungus ball cavity and/or surrounding infiltrate) or clinically (change 
in symptoms of cough and/or hemoptysis).
RESULTS
The patients' ages ranged from 26 to 50 years old, all of them had 
fungus ball in the upper lobes of the lungs and had tuberculosis as the 
underlying disease. The main symptoms were cough and hemoptysis 
that were classified as blood-streaked sputum, mild-to-moderate (< 
100 mL/24h). Four patients had hepatitis C. Fungal ball diagnostic was 
made by ID, direct mycological examination and culture of the respiratory 
tract samples. A. fumigatus was the etiologic agent of all cases (Table 1). 
The case 2 of this series in CT revealed multiple fungus balls (Fig.1 and 2). 
Table 1
Cases descriptions of six HIV positive patients with fungus ball
Patient No/
Age/Sex
CD4 
Count 
(Cells/µL)
Associated/ 
predisposing 
disease
Clinical
signs
Fungus ball
localization
Diagnostic
test of 
aspergillosis
HAART Treatment Outcome
1/28/M 566 TB,
Hepatitis C,
Hepatitis B.
Hemoptysis,
cough, dyspnea, 
fever,
chest pain.
LUL ID(+)
SpCult(+) 
Yes Itraconazole 
Embolization,
Radiotherapy
No change (10 
months)
2/26/M 161 TB,
Hepatitis C. Hemoptysis.
LUL and 
RLL
ID(+)
Sp DM(+)
Cult(+)
Yes Itraconazole No change 
(48 months)
3/42/M 138 TB, 
Hepatitis C, 
CMV,
adrenal failure.
Hemoptysis, 
cough, dyspnea.
RUL ID(+)
Sp DM(+)
Cult(+)
Yes Lobectomy No
Follow-up
4/50/M 540 TB,
Hepatitis C.
Hemoptysis,
cough, dyspnea.
LUL and 
RUL
ID(+)
Sp DM(+)
Cult(+)
Yes Itraconazole No
Follow-up
5/31/M Not done TB Hemoptysis,
cough,
fever.
LUL ID(+)
TBBX(+)
No Pleuropneumectomy No
Follow-up
6/34/F Not done TB Hemoptysis, 
cough.
RUL ID(+) No Itraconazole Symptomatic
Improvement 
(48 months)
Age and CD4 count at first presentation. TB: Tuberculosis; HAART: Highly active antiretroviral therapy; LUL: left upper lobe; RUL: right upper lobe; RLL: right lower 
lobe; Sp: sputum; TBBX: transbronchial biopsy; ID: immunodifusion for A. fumigatus; Cult: Culture; DM: Direct microscopy; F: Female; M: Male; CMV: cytomegalovirus. 
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Illustrative Case (Case 1): A 28-year-old male, presenting fever, 
dyspnea, chest pain, cough and hemoptysis for two months was admitted 
to the hospital. The patient had a chronic hepatopathy due to B and C 
hepatitis virus and had received an incomplete treatment for tuberculosis 
two years before when he had positive sputum smear for acid-fast bacilli 
and HIV test (enzyme-linked immunosorbent assay confirmed by Western 
blot). At the time of presentation his sputum was negative for staining 
of acid-fast bacilli but he was started on tuberculosis therapy because of 
previous incomplete treatment with zidovudina (AZT), didanosina (DDI) 
and sulfamethoxazol-trimetroprim (SMT-TMP).
Physical examination revealed a febrile and undernourished patient 
with digital clubbing. Wheezing and rales were noted in both lungs. A 
roentgenogram of the chest disclosed a total destruction of the left lung. 
The left upper lobe had a cavity containing a soft tissue mass (fungus 
ball). A. fumigatus was recovered in culture (performed in Sabouraud 
dextrose agar with chloramphenicol at 25 ˚C) and A. fumigatus ID was 
positive. Itraconazole (200 mg/day) was started, and at this moment his 
CD4 was 566 cells/µL. Seven months later he had another episode of 
hemoptysis so arterial embolization was made, followed by radiotherapy 
two months later. With ten months of treatment, the culture of the sputum 
on Sabouraud dextrose agar still revealed A. fumigatus and there was no 
radiological change. It was indicated the continuity of treatment with 
itraconazole outpatient.
DISCUSSION
Fungus ball in immunocompetent patients is well documented in 
the literature. However, few cases of this aspergillosis presentation in 
patients with AIDS were reported8,10.
Fungus ball had been described predominantly as a consequence of 
preexisting tuberculosis cavities, but other diseases are also implicated 
as precursors of this entity although less often. Some of them are related 
to immunodepression5. A previous study comparing HIV-infected and 
HIV-negative individuals found pneumocystosis as a predisposing factor 
in HIV-infected individuals as a risk factor for fungus ball1. In addition, 
another series of 20 cases describing fungus ball in HIV-infected patients 
also found eight cases of pneumocystosis as a predisposing factor7. This 
implication was not confirmed in our study, because no HIV patients with 
fungus ball had P. jirovecii infection associated.
The presentation and clinical course of pulmonary fungus ball 
in the HIV-infected patient differs in several ways from those in the 
immunocompetent patient17. HIV positive patients are particularly 
susceptible to cavitary lung disease, including pneumatoceles secondary 
to P. jirovecii pneumonia and tuberculosis, as well as necrotizing bacterial 
pneumonias1,8. 
All HIV patients included in the present study had moderate 
hemoptysis. In fact, these patients are less likely to have significant 
hemoptysis, which is much more common among the HIV-negative 
individual, 73% compared with 40% of HIV-infected individuals. On 
the other hand, they have a high risk of disease progression, including 
the development of possible semi-invasive illness1,8. Patients with 
fungus ball generally have one to four arcs of precipitation antibodies 
(immunodiffusion test). The absence of precipitating antibody in a small 
number of patients may be related to the presence of dead fungi, deficiency 
of gamma globulin, immunosuppressive therapy, or poor antigenicity of 
the pathogenic fungi14,24. Although our patients were immunosuppressed 
by HIV infection, their immunodiffusion characteristics were similar to 
immunocompetent patients, even those with low CD4 count, without 
false negative results. 
Surgery procedures are indicated in symptomatic patients due to 
the high risk of massive and fatal hemoptysis. Resection surgery is the 
treatment of choice for localized disease, simple fungus ball, in suitable 
candidates. Two patients of the present study were included in this group. 
Resection should only be undertaken if there is sufficient respiratory 
reserve and the resection removes minimal functioning pulmonary 
tissue1,8,11,23. Itraconazole, used as treatment in four of our patients, can 
be considered as the first choice in the therapy of fungus ball due to its 
Fig.1 - Spherical cavity (5 cm) within laminar pathological material localized in inferior 
right lobe. 
Fig. 2 - Left pulmonary parenchyma destruction with two cavities in the superior third. 
Upper cavity (3 cm diameter) within spherical mass, and cavity below (4 cm) within laminar 
pathological material.
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lipophilic characteristic, which results in a great concentration of the drug 
in the cavity of fungus balls26,28. Bronchial artery embolization, procedure 
also used in the illustrative case, although temporarily effective, has 
been used to occlude the vessel that supplies the bleeding site in patients 
experiencing hemoptysis. Additional treatments for hemoptysis have 
included radiotherapy7,18,20,23.
Given the fact that this was a retrospective study, there are some 
limitations as to monitoring and evaluation of treatment. However, 
tuberculosis seems to be the main risk factor to fungus ball in this 
study despite HIV status, or CD4 count. Thus, we alert clinicians to the 
importance of a constant and rigorous monitoring of the treatment and the 
evolution of HIV patients with tuberculosis, endemic disease in Brazil. 
RESUMO
Bola fúngica em pacientes HIV-infectados
Os fungos filamentosos são oportunistas de fagócitos, motivo pelo 
qual aspergilose é incomum em pacientes com Aids. A apresentação 
clínica depende do estado imune, tamanho do inóculo fúngico e doença de 
base. São relatados neste trabalho seis casos de bola fúngica em pacientes 
com Aids. Neste grupo, todos tiveram tuberculose como doença de base 
e hemoptise foi o principal sintoma. O diagnóstico da bola fúngica foi 
através da apresentação clínica, achados radiológicos combinados com 
imunodifusão radial dupla, exame micológico direto e cultivo do material 
do trato respiratório, sendo A. fumigatus o agente isolado. 
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